학술논문

발행년
-
(예 : 2010-2015)
'학술논문' 에서 검색결과 45건 | 목록 1~10
Academic Journal
Nogueira-Rodrigues A; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Rosa DD; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Suzuki DA; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Paulino E; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Landeiro LCG; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Scaranti M; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Madi MR; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.; Hoff PM; Sociedade Brasileira de Oncologia Clínica - São Paulo (SP), Brazil.
Publisher: Associação Médica Brasileira Country of Publication: Brazil NLM ID: 9308586 Publication Model: eCollection Cited Medium: Internet ISSN: 1806-9282 (Electronic) Linking ISSN: 01044230 NLM ISO Abbreviation: Rev Assoc Med Bras (1992) Subsets: MEDLINE
Academic Journal
de Andrade DAP; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; InORP Oncoclínicas Group, Ribeirão Preto, Brazil.; Guimarães APG; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; AC Camargo Cancer Center, São Paulo, Brazil.; de Melo AC; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Brazilian Nacional Cancer Institute - INCA, Rio de Janeiro, Brazil.; Nogueira-Rodrigues A; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.; Gomes LM; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; CPO Oncoclínicas Group, São Paulo, Brazil.; Scaranti M; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; DASA - Hospital 9 de Julho, São Paulo, Brazil.; Maia JML; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Cancer Treatment Center, MedRadius -, Maceió, Brazil.; Morelle AM; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital Moinhos de Vento, Porto Alegre, Brazil.; Santos CAAL; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.; Souza CP; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Barretos Cancer Hospital, Barretos, Brazil.; de Freitas D; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital Sírio-Libanês, São Paulo, Brazil.; Callegaro Filho D; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Paulino E; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Brazilian Nacional Cancer Institute - INCA, Rio de Janeiro, Brazil.; Júnior EWA; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; IHOC Oncoclínicas Group, Curitiba, Brazil.; Pimenta JM; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.; Dos Santos MB; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; CPO Oncoclínicas Group, São Paulo, Brazil.; de Almeida MS; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital do Coração HCOR Oncologia, São Paulo, Brazil.; Souza RP; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; AC Camargo Cancer Center, São Paulo, Brazil.; Cabral S; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Universidade de São Paulo, São Paulo, Brazil.; Maluf FC; Brazilian Gynecologic Oncology Group, EVA, São Paulo, Brazil.; Hospital Beneficiência Portuguesa de São Paulo, São Paulo, Brazil.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Academic Journal
Wanderley CWS; Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, Ribeirao Preto, Brazil.; Department of Pharmacology, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Brazil.; Correa TS; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.; Scaranti M; Oncologia DASA, Hospital Nove de Julho, São Paulo, Brazil.; Cunha FQ; Center for Research in Inflammatory Diseases (CRID), Ribeirao Preto Medical School, Ribeirao Preto, Brazil.; Department of Pharmacology, Ribeirao Preto Medical School, University of São Paulo, Ribeirao Preto, Brazil.; Barroso-Sousa R; Oncology Center, Hospital Sírio-Libanês, Brasília, Brazil.
Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Academic Journal
Guo C; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Chénard-Poirier M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Roda D; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; de Miguel M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Harris SJ; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Candilejo IM; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Sriskandarajah P; Division of Cancer Therapeutics, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Xu W; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Scaranti M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Constantinidou A; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; King J; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Parmar M; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Turner AJ; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Carreira S; Cancer Biomarkers, The Institute of Cancer Research, London, UK.; Riisnaes R; Cancer Biomarkers, The Institute of Cancer Research, London, UK.; Finneran L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.; Hall E; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.; Ishikawa Y; Translational Research Division, Chugai Pharmaceutical, Tokyo, Japan.; Nakai K; Translational Research Division, Chugai Pharmaceutical, Tokyo, Japan.; Tunariu N; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Basu B; Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.; Kaiser M; Division of Molecular Pathology and Myeloma Molecular Therapy Group, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Lopez JS; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Minchom A; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; de Bono JS; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK.; Banerji U; Drug Development Unit, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK. Electronic address: udai.banerji@icr.ac.uk.
Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Academic Journal
Terbuch A; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.; Tiu C; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Candilejo IM; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Division of Medical Oncology, START Madrid-HM Sanchinarro CIOCC Early Phase Program, Medical University Hospital of Sanchinarro, Madrid, Spain.; Scaranti M; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Curcean A; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Bar D; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Estevez Timon M; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Ameratunga M; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Monash University, Melbourne, Australia.; Ang JE; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Ratoff J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Epsom and St. Helier University Hospitals NHS Trust, Epsom, United Kingdom.; Minchom AR; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Banerji U; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; de Bono JS; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Tunariu N; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom.; Lopez JS; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, United Kingdom. juanita.lopez@icr.ac.uk.
Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Scaranti M; Hospital Sírio-Libanês, Sao Paulo, Brazil scarantimariana@gmail.com.; Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, Sao Paulo, SP, Brazil.; Mathias-Machado MC; Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira, Sao Paulo, SP, Brazil.; Guo C; Royal Marsden NHS Foundation Trust, London, London, UK.; The Institute of Cancer Research, London, London, UK.
Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Scaranti, M.
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어